Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063 AM2)
This study is currently recruiting participants.
Verified December 2013
by Merck Sharp & Dohme Corp.
Study NCT01390844 Information provided by Merck Sharp & Dohme Corp.
First Received on July 7, 2011. Last Updated on December 3, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C, Chronic
Additional conditions recognized in this trial
More general conditions related to this trial
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections
Interventions listed in this trial
Placebo to boceprevir
Peginterferon alfa-2b (PEG)
Cross-Over Boceprevir Treatment
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
Merck Sharp & Dohme Corp.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers